Ohr Pharmaceutical Promotes Jason S. Slakter, MD to Chief Executive Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Brean Capital Cuts Price Target on Ohr Pharmaceutical (OHRP) Following 3Q Results and Recent Management Changes
August 7, 2015 7:33 AM EDTBrean Capital maintained a Buy rating on Ohr Pharmaceutical (NASDAQ: OHRP), and cut the price target to $30.00 (from $34.00), following 3Q results and recent management changes. Ohr reported EPS of $(0.11) in its FY3Q15, versus consensus of $(0.19). Ohr recently replaced its CEO and founder Irach Taraporewala with CMO Jason Slakter, with Dr. Taraporewala assuming the position of CTO.
Analyst Jonathan Aschoff commented, "Ohr... More
Ohr Pharmaceutical (OHRP) Appoints New CEO
August 5, 2015 8:06 AM EDTOhr Pharmaceutical (Nasdaq: OHRP) announced that Jason S. Slakter, MD, has been appointed Chief Executive Officer, effective August 7, 2015. He succeeds CEO and founder Dr. Irach Taraporewala, who will become Chief Technology Officer and be responsible for the leadership and execution of the Company's sustained release drug development programs, among other responsibilities. Dr. Taraporewala will continue to serve on the Company's board of directors.
"We are delighted that Dr. Slakter has agreed to become Chief Executive Officer at Ohr. Since joining the company in 2014, he has shown tremendous leadership in moving our clinical programs... More
